Upload
virginia-perkins
View
230
Download
2
Tags:
Embed Size (px)
Citation preview
Obesity, diabetes andcardiovascular disease
http://www.bmb.leeds.ac.uk/illingworth/bioc3600/index.htm
Dr John IllingworthUniversity of Leeds
BIOC3600 / BMSC3145 / BIOL5215M / BIOL5235M (2010)
all slides
22
• Most adults in the UK are already overweight. Modern living ensures every generation is heavier than the last – `Passive Obesity’.
• By 2050 60% of men and 40% of women could be clinically obese. Without action, obesity-related diseases will cost the United Kingdom an extra £50 billion per year (almost double the UK Trade Gap).
• The obesity epidemic cannot be prevented by individual action alone and demands a societal approach.
• Tackling obesity requires far greater change than anything tried so far, and at multiple levels: personal, family, community and national.
• Preventing obesity is a societal challenge, similar to climate change. It requires partnership between government, science, business and civil society.
Tackling Obesities: Future Choices
Government Office for Science http://www.foresight.gov.uk
October 2007 and subsequent updates
33
definitions of obesity
Body mass index = weight (kg) / height (m)2
• 20-25 normal• 25-30 overweight• >30 obese
• BMI does not adequately distinguish fat from lean muscle mass.
• Separate norms should be used for men, women, children and for different races, but this is rarely done.
• Dual-wavelength X-ray absorptiometry is the best method to measure body composition, but this is rarely available.
• For many purposes a simple waist measurement is optimal, because this measures abdominal fat, which caries the highest risk.
44
obesity increases the risk of disease
Willet et al. Guidelines for Healthy Weight (1999) NEJM 341, 427 - 433
55
other conditions associated with obesity
• asthma • cancers (reproductive organs and gastro-intestinal tract) • Cushing's syndrome (excessive production of ACTH)• dyslipidaemias (abnormal blood lipids), hyperlipidaemia • dyspnoea (breathlessness) snoring and sleep apnoea • hiatus hernia and gastro-oesophageal reflux disease • kidney diseases • osteoarthritis / degenerative joint diseases • psychological problems • reproductive problems • varicose veins
Associations need not imply causality, and several of them are disputed, especially the asthma and cancer risks.
66
the most serious links:
• obesity
• hypertension
• type 2 diabetes
• cardiovascular diseases
Heart attacks and strokes are major causes of death and disability in the general population.
Low grade inflammation is the common factor.
77
88
Age Most common cause of death Second most common cause90+
Heart attack and chronic heart disease
Pneumonia85—89
Cerebrovascular disease (strokes)
80—8475—7970—7465—69
Lung cancer60—6455—59
50—5445—49
Breast cancer40—4435—3930—34
Motor vehicle accidentsDeaths due to drugs25—29
20—24
15—19
Other nervous disorders10—14Pedestrian hit by vehicle
5—91—4 Congenital heart defects
0 Perinatal conditions Sudden death, cause unknown
9
age at death 1981 – 200414.8 million deaths analysed by age and sex.
Data from Shaw et al “The Grim Reaper’s Road Map” page 2 ISBN 978 1 86134 824 1 Health Sciences Library WA 900 SHA Very few Britons die <50. Transport accidents and suicides cause few deaths overall, but these are preventable deaths.
9
10
loss of life expectancy
• Here is some information about the next slide, which shows the loss of life expectancy caused by different diseases.
• Diseases that kill early in life will obviously receive a greater weighting in this analysis.
• The following table underestimates female premature mortality because it uses the same “normal” life expectancy of 75 years for both women and men. [It would have been better to use 72 years for men and 78 for women.]
• Numerous individually rare diseases account for the missing 30% in the following table.
10
11
million years of life lost through diseaseCause of death before age 75 Males Females Totals % lost
Heart attack and chronic heart disease 12.40 4.08 16.48 19.16
Lung cancer 3.83 1.89 5.72 6.66
Cerebrovascular disease 2.37 2.03 4.41 5.13
Breast cancer 0.01 3.25 3.27 3.80
Motor vehicle accidents 1.97 0.50 2.48 2.88
Chronic lower respiratory diseases 1.40 0.88 2.29 2.66
Perinatal conditions 1.29 0.91 2.20 2.56
Pneumonia 1.19 0.80 1.99 2.31
Chronic liver disease 1.06 0.63 1.69 1.96
Sudden death, cause unknown 0.99 0.60 1.59 1.85
all other cancers 9.07 7.35 16.42 19.08
TOTALS (Britain, 1981-2004) 53.13 32.91 86.06 100.0011
12
the metabolic syndrome
This is a statistical association between six important clinical findings:
• Hypertension (high blood pressure)
• Dislipidaemia (raised LDL cholesterol)
• Type 2 diabetes (insulin resistance)
• Abdominal obesity (“beer belly”)
• Low-grade, systemic vascular inflammation
• Cardiovascular disease (atherosclerosis, neuropathies, retina, kidney, amputations, heart attacks, strokes)
12
13
inflammation – a common thread
Most terminal, disabling and debilitating diseases in older patients have substantial inflammatory components, for example:
• Most varieties of cardiovascular disease
• Neurodegenerative diseases – Alzheimers
• Respiratory diseases – asthma, emphysema
• Arthritis, osteoporosis and sarcopenia
• Kidney diseases, gut diseases (IBD, coeliac)
• Many types of cancer
Obesity may lead to an inflammatory state 13
14
cachexia• Greek word pronounced “ca –hexia” which means “poor
condition”.
• Cachexia is a hypermetabolic state where patients lose lean muscle mass.
• It is a common feature of terminal or life threatening diseases: chronic heart failure, AIDS, serious burns, tuberculosis, cancer…
• Characterised by insulin resistance and increased pro-inflammatory cytokines such as TNF-, IL-1 and IL-6
• Cachexia is an immediate threat to life, in contrast to the long-term threat from the metabolic syndrome, but these two conditions share several biochemical, physiological and immunological characteristics. 14
15
inflammation basics
• The classic signs are redness, heat, swelling, pain and loss of function.
• Initiated by a few immune cells resident in the tissue which detect foreign materials or tissue damage and release inflammatory cytokines.
• Cytokines cause vasodilation and stimulate blood flow (redness, heat), increase capillary permeability leading to the loss of plasma proteins and fluid to the interstitial space (swelling) and attract other immune cells into the tissue from the blood (recruitment, positive feedback).
• Lymphatic drainage flushes antigens into lymph nodes, initiating an adaptive immune response.
15
16
types of inflammation
Acute• Needs stimulation• Lasts only a few days• Pre-programmed “task
and finish” system
Chronic• Self-perpetuating • May persist for years• Simultaneous tissue
destruction and repair
There are dozens of inflammatory mediators, which alter in importance as the process develops, may have stimulatory or inhibitory actions. Release of histamine from mast cells is an early event, also eicosanoid production (prostaglandins, prostacyclins, thromboxanes and leucotrienes) from long chain poly-unsaturated fats. At least 20 protein cytokines are involved, also reactive oxygen species (ROS). CRP (C-reactive protein) is a marker measured in blood.
16
17
0
20
40
60
80
100
120
140
160
180
200
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
1940 1960 1980 2000
sp
ec
ialis
t p
ap
ers
tota
l n
um
be
r
year
papers published on inflammation
total
acute
chronic
17
18
reactive oxygen species (ROS)• ROS are free radicals produced during inflammation,
and also at other times
• Includes superoxide (O2.-) hydroxyl (OH.) and related
molecules such as hydrogen peroxide, peroxynitrite, hypochlorite …
• ROS are used by macrophages for killing bacteria, they may also damage tissues and have a signalling role.
• ROS destroy nitric oxide, which otherwise increases blood flow in arterioles.
• ROS are destroyed by superoxide dismutases (SOD) a diverse group of unrelated enzymes of whose genetic absence causes serious disease, assisted by catalase and glutathione peroxidase. 18
19
matrix metalloproteinases (MMPs)
• MMPs are a family of zinc-dependent endopeptidases
• Degrade extracellular matrix proteins, such as collagen, they also release various messengers that are tethered to the plasmalemma
• Secreted initially in an inactive form, they may be activated by proteolytic cascades
• Heavily involved in tissue remodelling
• Major roles in inflammation, metastasis
• Cause tissue damage in chronic disease
19
2020
other cardiovascular risk factors• Blood clotting disorders [fibrinogen / plasminogen activator].
• Familial hypercholesterolaemia and dyslipidaemias(caused by genetics rather than lifestyle choices)
• Old age [over 45 years for men, 55 years for women].
• South Asian ancestry, family history [affected male relatives under 55 years, females under 65 years].
• Male gender, post menopausal women (oestrogens protect).
• Homocysteinaemia [strong but non-causal association].
• Oral contraceptives [minor risk with low dose pills].
• Poverty and low socio-economic status.
• Tobacco smoking [very high risk].
• Lack of physical exercise. }modifiable factors
21
racial differencesThere are significant racial differences in the incidence of diabetes and cardiovascular disease:
• South Asians (from Bangladesh, India & Pakistan) are particularly susceptible to type 2 diabetes and coronary artery disease, but have a lower incidence of peripheral arterial disease.
• Blacks have a higher incidence of strokes, but a lower incidence of coronary artery disease.
• Whites appear to have a higher incidence of abdominal aortic aneurysm, though the data for other ethnic groups may be incomplete.
21
22
‘all-cause’ mortality in Leeds
22
men women
These maps show age-standardised ‘all-cause’ mortality statistics from NHS Leeds, broken down by electoral wards. The data are displayed on a spectral scale, where dark green is best, red is worst. Death rates near Leeds city centre are three times higher than those in the leafy suburbs, corresponding to a ten-year difference in life expectancy.
23
cardiovascular diseases• Microvascular disease
– typically affects small blood vessels supplying the kidneys, retina and nervous system
– very sensitive to blood glucose control, but unaffected by blood lipid profiles.
– causes glomerulonephritis, blindness, neuropathies
• Macrovascular disease– typically affects large arteries such as the aorta, coronary
arteries, carotids, major limb vessels
– very sensitive to blood lipid profiles, but relatively insensitive to blood glucose control
– atherosclerosis, leading to heart attacks, strokes, angina, intermittent claudication, ulcers, gangrene, amputations
– abdominal aortic aneurisms (distinct pathology)23
2424
pathogenic mechanisms
• endothelial dysfunction, including major inflammatory or auto-immune components, is a common mechanism in cardiovascular diseases.
• diabetes: non-enzymic glycation of connective tissue proteins leads to microangiopathy and kidney, retinal and neurological problems.
• diabetics also have adverse blood lipid profiles causing atherosclerosis and large vessel disease.
• hypertension: mechanical damage to vascular endothelium increases the risk of clot formation.
• hypertension also increases myocardial oxygen demand because the heart has more work to do.
25
Endothelial Dysfunction: The Common Consequence in Diabetes and Hypertension.Wong, Wing; Wong, Siu; Tian, Xiao; Huang, Yu
Journal of Cardiovascular Pharmacology. 55(4):300-307, April 2010. DOI: 10.1097/FJC.0b013e3181d7671c
Vasodilative and vasoconstrictive pathways in the vascular wall. * decrease # increase
ACh, acetylcholine; M, muscarinic receptor; ONOO-, peroxynitrite; sGC, guanylate cyclase; AC, adenylate cyclase; AA, arachidonic acid; IPR, IP receptor; TPR, TP receptor; FPR, FP receptor; EPR, EP receptor; DPR, DP receptor.
2626
drugs for obesity, diabetes & cardiovascular diseaseexample type principal targets typical indication
ramipril ACE inhibitor arteriolar smooth muscle hypertension
valsartan AR blocker arteriolar smooth muscle hypertension
metoprolol -blocker cardiac muscle hypertension
nifedipine Ca++ antagonist cardiac & smooth muscle hypertension
frumil diuretic kidney tubules (loop of Henle) heart failure
nitroglycerine organic nitrate venous smooth muscle angina
aspirin NSAID non-specific COX1 & COX2 old age?
clopidogrel anti-platelet platelet ADP receptor atherosclerosis
heparin anti-coagulant vascular endothelium atherosclerosis
warfarin anti-coagulant liver (clotting factor synthesis) atherosclerosis
streptokinase clot dissolution blood clots acute MI
lovastatin statin liver HMG-CoA reductase dislipidaemia
gemfibrozil fibrate PPAR- in many tissues dislipidaemia
metformin biguanide liver AMPK type 2 diabetes
exenatide incretin pancreatic -cells type 2 diabetes
glipizide sulphonylurea pancreatic -cells type 2 diabetes
pioglitazone thiazolidinedione PPAR- in many tissues type 2 diabetes
acarbose amylase inhibitor small intestinal lumen type 2 diabetes
orlistat lipase inhibitor small intestinal lumen diabetes, obesity
sibutramine SSRI central nervous system obesity
27
drug side effectsMany of these drugs are useful, but may bring unwanted side effects. Several have been withdrawn for safety reasons, for example:
• Dexfenfluramine – improves weight loss, but causes pulmonary hypertension and heart valve defects
• Rimonabant – improves weight loss, but causes depression and increases the risk of suicide
• Sibutramine – improves weight loss, but increases the overall risk of heart attacks and strokes
• Rosiglitazone – improves diabetes, but increases the risk of heart failure
• Increased physical activity costs little, has very few side effects, and is more effective than most drugs.
27
28
exercise – a common therapy• The health benefits from physical activity were known to
the Ancient Greeks, but for centuries this knowledge was ignored.
• Interest has re-awakened over the last fifty years, which have seen an enormous increase in research papers on exercise and health.
• Lean, physically active individuals suffer less depression and live significantly longer than their less active, obese peers.
• Moderate exercise has anti-inflammatory actions, reduces blood viscosity and improves vasodilation, which may partly explain the effect.
28
2929
3030
exercise and “all cause” mortality• Katzmarzyk et al (2003)
Obesity Reviews 4, 257–290
• Meta-analysis of 57 previous studies, world wide.
• Measured ‘all cause’ mortality with and without adiposity measurements
• Physically active people had a 20% lower death rate than inactive peers, regardless of adiposity
• Raised BMI > 25 kg/m2 resulted in a 24% increase in mortality, regardless of physical activity.
3131
dose-response curve for exercise
Kokkinos et al (2009) Am J Hypertens 22, 735-741
32
effect of leisure-time physical activity
32
Byberg, L. et al. BMJ 2009; 338:b688
3333
macrovascular disease• Atherosclerosis is an inflammatory process, strongly
associated with adverse blood lipid profiles.• Desirable fasting lipid levels:
– Total cholesterol <5.2mM (<200mg/dL)
– LDL cholesterol <3.4mM (<130mg/dL)
– HDL cholesterol >1.6mM (>60mg/dL)
• Inflammation is Th1 based, exacerbated by TNF- and angiotensin II, and suppressed by Tregs
• Inadequate nitric oxide production may be important• Aneurysms are also inflammatory lesions that weaken &
remodel the outer regions of the blood vessel wall. They are exacerbated by smoking and angiotensin II, and are more closely associated with ROS and oxidative stress.
3434
atherosclerotic plaques
Galkina & Ley (2009) Annu. Rev. Immunol. 27, 165-197.
3535
atherosclerosis (1)• Progressive, inflammatory process mainly affecting the walls of the
larger arteries. Healthy vessels with an intact endothelium are highly resistant to the formation of clots.
• Atherosclerosis starts with intimal thickening and “fatty streaks” in the vessel wall, which gradually transform into atheromatous plaques.
• Macrophages invade the structure, phagocytose and partly degrade the lipid, forming foam cells. Partially oxidised lipid accumulates within the plaque and the normal intimal lining of the blood vessel is transformed into a collagen-rich “cap”.
• The plaque enlarges and may partially calcify. There is damage to the underlying smooth muscle in the vessel wall. Necrotic interior, unless new vessels develop in the plaque and supply the interior with blood.
• Eventually the cap ruptures, or the internal vessels burst, exposing the highly thrombogenic interior directly to the bloodstream.
• A thrombus (clot) forms, which may either obstruct the vessel locally, or detach and embolise in a narrower vessel further down.
3636
atherosclerosis (2)
Intimal thickening is very common in older subjects, and may be a natural adaptation to ageing.
The thickening “P” may be asymmetric.
IEL = inner elastic lamina.
From Wheater’s Basic Histopathology, page 88, figure 8.3
3737
atherosclerosis (3)
C = collagen cap; F = fibrous tissue; L = free lipidfrom Wheater’s Basic Histopathology, p 90
3838
atherosclerosis (4)F = foam cells; C = free lipid
Wheater’s Basic Histopathology p. 89
3939
atherosclerosis (5)
A = plaque
T = thrombus
C = p.m. clot
from
Wheater
p. 94
4040
acute myocardial infarction (AMI)• Caused by obstruction of a coronary artery by thrombus
leading to death of the downstream muscle tissue.
• AMI may be painless in elderly patients, but is usually suspected after intense crushing chest pain, nausea, vomiting, sweating and extreme distress.
• Diagnosis is confirmed from electrocardiogram changes and the release of cardiac-specific troponin variants into the blood stream from dying cells.
• The key treatment objective is rapid thrombolysis with “clot buster” enzymes, or surgical removal of the obstruction.
• Cardiac patients may subsequently develop chronic heart failure and / or cachexia [means “poor condition”].
• Obesity is a risk factor for both conditions, BUT cachectic patients survive better if they are fat.
4141
basic cardiovascular physiology (1)• Each beat, the heart normally expels most of the blood
that is presented to it for pumping. Atrial filling pressures rise as the venous flow to the heart increases, and the chambers become distended during diastole by the returning blood. Greater initial distension stimulates more forceful contractions. This is Starling’s Law.
• When cardiac contractility is poor, central venous blood pressures increase to abnormally high levels before they can adequately stretch the ventricles to maintain cardiac output. This situation is known as heart failure. It does not mean that the heart has stopped beating.
• High venous pressures lead to fluid accumulation in the tissues. Swollen ankles indicate right side failure, while left side failure is manifest by fluid in the lungs.
4242
basic cardiovascular physiology (2)
• We regulate blood volume, blood osmolarity and blood pressure, but these control systems overlap.
• The atria sense total blood volume from the venous filling pressure and resulting atrial stretch. They secrete atrial natriuretic peptide in response to stretching, which increases the loss of salt and water via the kidneys.
• The hypothalamus senses blood osmolarity and responds by secreting vasopressin via the posterior pituitary. This restricts water losses via the kidney.
• Arterial baroceptors monitor blood pressure, and trigger vasodilation and a slower heart rate via the autonomic nervous system when the blood pressure is too high.
4343
defence of salt and water balance
4444
basic cardiovascular physiology (3)• In addition, the autonomic nervous system directly
modulates the renin – angiotensin system, which normally maintains an adequate renal blood flow.
• Sensory cells in the kidney respond to low perfusion by secreting a protease, renin, which cleaves an 2 globulin produced by the liver to generate angiotensin I.
• Angiotensin converting enzyme (ACE) in the lungs cleaves more amino acids to generate angiotensin II.
• Angiotensin II causes vasoconstriction and increases blood pressure. It also stimulates adrenal production of aldosterone, a mineralocorticoid which favours sodium retention by the kidneys and expands the blood volume. Angiotensin II acts on the hypothalamus to stimulate vasopressin release and increases thirst.
4545
46
preload, afterload & contractility• The venous pressure which returns blood to the heart,
fills and distends the ventricles during diastole is often referred to as preload.
• The aortic pressure seen by the heart during systole (contraction) is often referred to as afterload.
• The relationship between preload and afterload depends on the cardiac contractility.
• Drugs such as diuretics and nitroglycerine reduce the preload, and thereby relieve many symptoms of angina and heart failure.
• Drugs such as ACE inhibitors, -blockers and calcium blockers reduce the afterload and / or contractility.
• Different classes of cardiac drug may achieve similar effects, but rely on different mechanisms.
47
0
50
100
150
200
250
0 10 20 30 40
preload
afte
rloa
dStarling’s law
low contractility
heart failure
healthy
inotropic effect
4848
peripheral vascular disease
In addition to a much greater incidence of strokes and coronary artery disease, diabetic patients are prone to atherosclerotic obstruction and poor circulation through the small arteries supplying the lower limbs and feet. This under-perfusion results first in diabetic foot ulcers, which may progress to gangrene, requiring amputations. This is another manifestation of macrovascular disease.
Intermittent claudication is pain from poorly perfused skeletal muscles. Like angina (which it closely resembles) this pain is exacerbated by exercise and relieved by rest.
4949
microvascular disease• Small vessel disease most often presents as sensory and
autonomic neuropathies, kidney and retinal disease.
• All these conditions are major causes of ill health in the general population.
• Thickening of the capillary basement membrane is a consistent early feature of microvascular disease, and contributes to tissue hypoxia and poor wound healing.
• Small vessel disease can be minimised by good glycaemic (blood glucose) control.
• Large vessel disease is little affected by glycaemic control.
• Inflammation plays a major role in both microvascular and macrovascular disease.
5050
diabetic retinopathy
Fragile new blood vessels develop in the proliferative form, which is more severe.
5151
NFB – nuclear factor kappa B (1)
• NFKB are a group of proteins regulating gene expression that are expressed in many types of cells that signal via cytokines
• NFKB are activated by numerous inflammatory stimuli, and inhibited by corticosteroids
• NFKB activation typically (ideally?) produces a transient, time limited nuclear response
• NFKB activation generates further inflammatory messengers
• NFKB regulation can therefore get “stuck in a rut” leading to persistent inflammation
• Over-activity of NFKB is associated with chronic inflammatory diseases such as atherosclerosis, lung fibrosis, arthritis, asthma, septic shock, and glomerulonephritis.
• Prolonged inhibition of NFKB is associated with apoptosis, inappropriate immune cell development and delayed cell growth.
5252
NFB – nuclear factor kappa B (2)
NFKB activators examples
cytokines tumor necrosis factor (TNF),interleukin-1 (IL-1),interleukin-17 (IL-17)
protein kinase C activators
phorbol esters, platelet-activating factor
oxidants hydrogen peroxide, ozone
viruses rhinovirus, influenzavirus, Epstein–Barr virus, cytomegalovirus, adenovirus
immune stimuli antigens, phytohemagglutinin,anti-CD3 antibodies (by means of T-lymphocyte activation)
other lipopolysaccharide, ultraviolet radiation
5353
NFB – nuclear factor kappa B (3)
NFKB targets examples
pro-inflammatory cytokines
various granulocyte / macrophage colony stimulating factors, TNF , IL-1, IL-2, IL-6
chemokines IL-8, gro-, gro-, gro-, eotaxin, macrophage inflammatory protein 1, macrophage chemotactic protein 1,
inflammatory enzymes
inducible nitric oxide synthase (iNOS), inducible cyclo-oxygenase-2, 5-lipoxygenase, cytosolic phospholipase A2
cell adhesion molecules
intracellular adhesion molecule 1, vascular cell adhesion molecule (VCAM), E-selectin
receptors IL-2 receptor ( chain)T-cell receptor ( chain)
5454
NFB – nuclear factor kappa B (4)
• NFKB1 / NFKB2 bind either REL / RELA / RELB to form the NFKB complex
• I- inactivates NFKB by trapping it in the cytoplasm
• Kinases IKBKA / IKBKB phosphorylate I-, causing ubiquitination and destruction, and thereby activate NFKB
• NFKB complex translocates to the nucleus and binds motifs such as 5’ GGGRNNYYCC 3’ (where R is an A or G purine; and Y is a C or T pyrimidine).
5555
NFB – nuclear factor kappa B (5)
• Barnes & Karin (1997) NEJM 336, 1066-1071
5656
NFB – nuclear factor kappa B (6)• In mice, obesity activates hepatic NFKB causing chronic low level
inflammation. Activation of NFKB by other routes produces a very similar outcome, resembling type 2 diabetes. See: Cai et al (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa-B. Nature Med. 11, 183-190.
• Both NFKB genes produce alternate products with antagonistic functions. The short (amino terminal) versions p50 & p52 are pro-inflammatory, but the full length p105 & p100 are anti-inflammatory IKBs that sequester the short forms in the cytosol. See: Pereira & Oakley (2008) Nuclear factor-B1: Regulation and function. Int. J. Biochem. & Cell Biology 40, 1425–1430.
• Outputs from the NFKB system can be oscillatory, and oscillatory stimuli generate various outcomes, depending on the stimulation frequency. See: Ashall et al (2009) Pulsatile stimulation determines timing and specificity of NF-kappa-B-dependent transcription. Science 324, 242-246.
5757
peroxisome metabolism
• Peroxisomes handle big, awkward shaped lipids and degrade them to more manageable chunks that are processed by the mitochondria.
• Peroxisomal metabolism does not directly yield any ATP
5858
PPARs: peroxisome proliferator activated receptors • Peroxisome proliferators are a diverse group of compounds including
various natural lipids, anti-diabetic drugs & plasticisers (including some used in food containers) that increase peroxisomes in cells.
• PPARs are transcription factors that bind peroxisome proliferators and form heterodimers with retinoic acid binding proteins.
• All PPARs regulate genes involved in fat metabolism & inflammation.
• PPAR- active in liver, skeletal muscle, heart & kidney; regulates fatty acid uptake and oxidation, inflammation & vascular function.
• PPAR-/ is ubiquitously expressed, regulates fatty acid metabolism, muscle fibre types & suppresses macrophage-triggered inflammation.
• PPAR- active in white & brown adipose tissue, colon, endothelial & vascular smooth muscle cells and to a lesser extent in immune cells. Regulates adipocyte proliferation and differentiation. Improves insulin sensitivity by promoting fat storage and inhibiting adipokine synthesis. Requires PGC-1 to activate brown fat thermogenesis.
5959
Duan et al (2009) PPARs: the vasculature, inflammation and hypertension. Current Opinion in Nephrology & Hypertension 18(2), 128–133.
6060
PPARs & cardiovascular drugs• PPARs are the intracellular targets for two important groups of
cardiovascular drugs:
• Fibrates (e.g. gemfibrozil, bezafibrate, fenofibrate) activate PPAR- They reduce blood triglycerides & raise HDL cholesterol in men & post-menopausal women, may help to prevent both macrovascular (atherosclerosis & strokes) and microvascular (kidney, nerves & retina) diabetic complications.
• Thiazolidinediones (e.g. rosiglitazone, pioglitazone, troglitazone) activate PPAR-They improve insulin sensitivity of target tissues, with microvascular benefits in diabetes, but also cause unwanted weight gain, and problems with bone loss.
• In addition, compounds such as oleoylethanolamide (OEA) bind to intestinal PPAR- and reduce food intake by prolonging eating latency. (OEA is closely related to the endocannabinoids, but is not itself a cannabinoid.)
6161
Effects of TZDs pioglitazone / rosiglitazone on cardiovascular risk factors and surrogate markers
lipid profile endothelial function vascular parameters inflammation
↓ free fatty acids ↑ flow-mediated dilation
↑ coronary reserve ↓ c-reactive protein
↑ LDL particle size ↑ insulin-dependent endothelial NO release
↓ pulse wave velocity ↓ white cell count
↑ lipoprotein a ↓ oxidative stress ↓ wall thickness ↓/0 interleukin-6
↑/(↑) HDL ↓ oxidized LDL ↑ endothelial function ↓ ICAM and VCAM
↓/0 LDL / HDL ratio blood clotting ↓ albumin excretion ↓ TNF-α and MCP-1
↓/↑ triglycerides ↓ PAI-1 fat distribution ↓ MMP-9
hemodynamics ↓ fibrinogen ↓ visceral fat ↓ soluble CD40 ligand
↑ blood volume ↓ platelet aggregation ↑ subcutaneous fat ↓ adiponectin
↓ blood pressure ↓ endothelin-1 ↓ hepatic fat content ↓ serum amyloid A
but TZDs increase the risk of heart failure, MAY increase risk of MI.
ICAM — intercellular adhesion molecules; MCP-1 — monocyte-chemoattractant protein-1; MI — myocardial infarction; MMP-9 — Matrix metalloproteinase-9; PAI-1 — plasminogen activator inhibitor 1;VCAM — vascular cell adhesion molecules.
6262
normal blood glucose regulation
bloodglucose
physiologicassessment
short termresponse
long termresponse
>6mM too high:
secrete insulin
make liver glycogen, let glucose into cells
make triglyceride (lipogenesis)
~5mM OK ongoing turnover and metabolism
<4mM too low:
secrete glucagon & adrenalin
split liver glycogen, exclude glucose from most cells, except in emergencies
make glucose (gluconeogenesis)
mobilise fat and protein stores
63
What if blood [glucose] is wrong?
• Too low: people feel weak, bad tempered, cold and hungry – unpleasant sensation.
• Too high: (diabetes) causes no sensations, unless it is enormous, when patients start to urinate uncontrollably because their kidneys can’t cope.
• BUT – high blood glucose reacts non-enzymically with amino groups on blood and tissue proteins.
• This protein glycation causes serious damage.
• The essence of successful diabetes therapy is good glycaemic control.
64
glycated haemoglobin reflects risk
Glycated Hgb Diabetes CAD Stroke Death
< 5 % 0.53 0.95 1.09 1.48
5.0 - 5.5% 1.00 1.00 1.00 1.00
5.5 - < 6.0% 1.80 1.25 1.16 1.19
6.0 - < 6.5% 4.03 1.88 2.19 1.61
< 6.5% 10.40 2.46 2.96 1.71
• Selvin et al (2010) N Engl J Med. 362, 800-811 followed long term outcomes after measuring glycated Hb
• Low glycated Hb meant less risk of developing diabetes• BUT overall survival was better when glycated Hb was in
the normal range.64
6565
advanced glycation end-products (1)
• Elevated blood glucose causes protein glycation.
• Rearrangement and oxidation produces a variety of cross-linked Advanced Glycation End-products [AGEs] which are highly immunogenic
• Glycated haemoglobin is used for diagnosis, BUT
• Glycated endothelial proteins do the real damage.
6666
advanced glycation end-products (2)
Nessar Ahmed (2005) Advanced glycation endproducts — role in pathology of diabetic complications. Diabetes Research and Clinical Practice 67(1), 3-21
6767
6868
Soro-Paavonen et al (2008) Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of
Atherosclerosis in Diabetes Diabetes 57: 2461 – 2469.
6969
AGE inhibitors
• Figarola et al (2003) LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 46(8), 1140-1152.
• Figarola et al (2007) Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes 56(3), 647-655.
• Figarola et al. (2008) LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia 51(5), 882-891.
• Bhatwadekar et al. (2008) A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. Brit. J. Ophthalm. 92(4), 545-547.
7070
7171
7272Copyright ©2009 American Society of Nephrology
Coughlan, M. T. et al. J Am Soc Nephrol 2009;20:742-752
7373
what is diabetes mellitus?
● Heterogeneous group of disorders of carbohydrate metabolism that result in hyperglycaemia
● WHO diagnostic criteria for diabetes (2002)
Symptoms of diabetes1 plus casual1 plasma [glucose] >11.1 mmol/L
– OR fasting2 plasma [glucose] > 7.0 mmol/L
– OR plasma [glucose] >11.1 mmol/L 2h post 75g oral glucose load
1 Classic symptoms include polydipsia, polyuria and unexplained weight loss. Casual means any time of day without regard for last meal
2 Fasting means no caloric intake for at least 8 h
Diabetes from Greek for “siphon”
Mellitus from Latin for “sweet like honey”
7474
why is diabetes important?
● ~ 2.5 million cases in UK (October 2008 GP figures, yearly increase up more than 2-fold over 2006/07 increase)*
● ~ 750,000 cases in UK still undiagnosed
● 246 million cases worldwide (International Diabetes Foundation figures for 2006)
● Predicted worldwide incidence 380 million by 2025
*Comments from Chief Executive of Diabetes UK on 20th October 2008:
“ .... there is no getting away from the fact that this large increase is linked to the obesity crisis. Diabetes is one of the biggest health challenges facing the UK today. It causes heart disease, stroke, amputations, kidney failure and blindness, and more deaths than breast and prostate cancer. The NHS already spends one million pounds an hour on diabetes.”
7575
history of diabetes and insulin
LangerhansLangerhans
Ebers papyrus, 1550 BCFirst description
Charaka Samhita, ~300 BC2 types of diabetes
Paul Langerhans, 1869Islets of Langerhans
Banting, Best & Collip, 1922Isolation of insulin for patient treatment
Margery
Fred Sanger, 1953Insulin sequence
Dorothy Hodgkin, 1969Insulin structure
Ullrich, Ebina et al., 1985Insulin receptor cloning
Many, 1985-2008Signal transduction
7676
two types of diabetes mellitus
● Type 1 [mainly juvenile onset]
– 5-15% of cases
– inability to produce insulin
● Type 2 [mainly maturity onset]
– 85-95% of cases
– resistance to the normal action of insulin, and / or inability to produce sufficient insulin
– MODY = “maturity onset diabetes in the young”
Rosalyn Yallow & Solomon BersonRadioimmunoassay (RIA) 1959
7777
type 1 diabetes mellitus (T1DM) ● < 20% of diabetics (approx 1 in 300)
● Age at onset usually < 30 years (peaks at 12-15 years, hence the formerly-used term “Juvenile Onset Diabetes Mellitus”)
● Appearance of symptoms rapid, may be life-threatening:
– Hyperglycaemia leading to osmotic diuresis (glycosuria) and unquenchable thirst
– Ravening hunger & weight loss (up to 15 lbs in 2 weeks), tiredness
– Tendency to life-threatening ketosis (hyperventilation, vomiting, drowsiness and coma)
● Blood [insulin] low, always needs treatment with insulin
● Increased prevalence in relatives, association with MHC genes (involved in antigen presentation), but <50% concordance in identical twins
7878
Non-Obese Diabetic (NOD) mouse model
Type 1 Diabetes Mellitus (70% of females, 10% of males) BUT the incidence depends on the microbial environment in which the mice raised
6 months
MHC class II
antigenic peptide mutations
T-cell mediated autoimmune destruction of pancreatic -cells
(For immunology afficionados only, see Wen et al. (2008) Nature 455, 1109-1113)
7979
pathogenesis & treatment of T1DM● Apparent rapid onset of symptoms comes after several years gradual
destruction of -cells
● 95% of IDDM patients carry at least one HLA-DR3 or HLA-DR4 allele, in comparison to 50% of normal individuals
● Possible association with virus infection may reflect similarity between -cell proteins and viral proteins:
● Current treatment – insulin injections, insulin pumps
● Future treatments – inhaled insulin (but Exubera withdrawn in late 2007), insulin pumps, islet transplantation, production of -cells from stem cells, etc.
Coxsackievirus protein PC-2
-cell glutamic acid decarboxylase (GAD)
AMLIARYKMFPEVKEKGMAAVPRL
FIEWLKVKILPEVKEKHEF-LSRL
8080
type 2 diabetes mellitus (T2DM)
● > 80% of diabetics
● Age at onset usually > 30, appearance of symptoms slow. Ketosis rare.
● Often associated with obesity. No HLA association but family history of diabetes common (usually >70% concordance in identical twins): i.e. stems from combination of environmental & genetic factors.
● Often associated with peripheral insulin resistance - insulin is less able to stimulate glucose uptake or to inhibit hepatic glucose production.
● Insulin secretion by pancreas persists (initially insulin levels may be elevated and receptors downregulated), but insulin release in response to glucose is impaired and cannot compensate for insulin resistance.
● Commonly managed by diet, exercise and oral hypoglycaemic agents:
– sulphonylureas and meglitinides - promote insulin release;
– biguanides and thiazolidinediones - increase sensitivity to insulin.
8181
pathogenesis of T2DM
Insulin sensitivity
Insulin secretion
Years before onset of diabetes
25 15 5 01020
Decreased sensitivity to insulin precedes fall in insulin secretion
normal
normal
patient
patient sen
sitiv
ity
% Ideal body weight
Offspring of Type 2 DM
Controls (no relatives with Type 2DM)
100 160
Impact of “diabetogenes” on obesity-induced insulin resistance
Obesity affects sensitivity to insulin
– genes plus environment, but we can’t find the genes...
82
diabetes treatment strategies
therapy type 1 type 2
Insulin injections (usually a mixture of short-acting and long-acting varieties)
always needed
avoid if possible
Reduce the need for insulin by cutting out easily digested carbohydrates
helpful helpful
Lifestyle changes: increased exercise, calorie or carbohydrate restricted diet
helpful first choice
Increase insulin sensitivity using oral hypoglycaemic drugs (e.g. metformin)
helpful second best
Stimulate insulin production using oral hypoglycaemic drugs (e.g. glimepiride)
useless third best
8383
reducing the need for insulin• Foods high in sugar or simple polysaccharides break down quickly in
the gut, and generate large peaks of free glucose in the portal vein.
• Large quantities of insulin are then required to stabilise the blood glucose concentration.
• If digestion is delayed the glucose peak becomes longer and flatter (although no smaller in total volume) but less insulin is needed to maintain blood glucose near 5mM.
• Digestion can be delayed or prevented with enzyme inhibitors like acarbose. Bacterial fermentation may become a problem.
• Alternatively, patients may be advised to eat foods with a low glycaemic index, which break down more slowly in the gut.
• Such foods often include “wholegrain” products, containing complex carbohydrates, which are less easily hydrolysed, and less physically accessible to digestive enzymes. Reduced cooking and less refined sugar may also be helpful.
84
lifestyle changes are effective
Parameter Lifestyle
intervention Support & education
p
Weight loss (%) −6.15 −0.88 <0.001
Treadmill fitness (% METS) 12.74 1.96 <0.001
Hemoglobin A1c (%) −0.36 −0.09 <0.001
Systolic pressure (mm Hg) −5.33 −2.97 <0.001
Diastolic pressure (mm Hg) −2.92 −2.48 <0.01
HDL-C (mg/dL) 3.67 1.97 <0.001
Triglycerides (mg/dL) −25.56 −19.75 <0.001
• Wing et al (2010) Long-term Effects of a Lifestyle Intervention on Weight and Cardiovascular Risk Factors in Individuals With Type 2 Diabetes Mellitus. Archives of Internal Medicine 170, 1566-1575.
• Exercise + low fat diet, but would low carbs have been better? 84
85
gestational diabetes• All types of diabetic mothers often produce excessively
large babies – this is known as “macrosomia”.• High maternal glucose stimulates fetal insulin production
which acts as a growth factor.• Insulin resistance sometimes develops transiently during
pregnancy, especially during the third trimester, and may progress to “gestational diabetes mellitus” (GDM).
• Both conditions normally resolve after the baby has been born, but these mothers face increased long term risk of developing type 2 diabetes.
• Maternal obesity increases the risk of GDM.• Diet and resistance exercise improve glycaemic control
and reduce the need for insulin in GDM, but if necessary metformin and insulin are safe to use in pregnancy.
86
periodontal disease• Gingivitis – inflammation of the gums with bleeding and
sponginess caused by pathogens in dental plaque.• Periodontitis – inflammation of the tissues supporting the
teeth, leading to destruction of the periodontal ligament, damage to alveolar bone and tooth loss.
• Periodontal bacteria readily enter the circulation, causing transient bacteraemia. They sometimes colonise artificial heart valves or cause bacterial endocarditis.
• Treatment of periodontal inflammation reduces circulating levels of CRP and IL-6.
• Gum disease and heart disease correlate with social class.• There is a clear two-way relationship between diabetes and
gum disease, but the correlation between gum disease and cardiovascular disease is still disputed.
8787
pancreatic islets• the pancreas has two functions
• exocrine acinar cells manufacture and secrete a variety of digestive enzymes into the gut
• endocrine islet cells manufacture and release a variety of peptide hormones into the portal vein
• islet stem cells have a local gut origin, but the autonomic nerves that control them develop from neural crest
• all varieties of islet cell are ultimately derived from the same type of stem cell
types of islet cells:
• 20% α cells – glucagon• 70% β cells – insulin + amylin• 5% δ cells – somatostatin• 5% other minor cell types
8888
insulin basics• Insulin and amylin are both manufactured by the β cells, and
released primarily in response to raised blood glucose, although there are many other stimuli.
• Insulin suppresses glucose output from the liver, and promotes glucose metabolism by most tissues other than brain, thereby returning blood glucose to the target value near 5mM.
• Insulin has numerous actions on carbohydrate, fat and protein metabolism, which differ from one tissue to another:
– More glycogen synthesis in liver, stops glycogenolysis.
– More glycolysis + lipogenesis in liver, stops lipolysis + gluconeogenesis.
– More glucose transport into most peripheral tissues, except for red blood cells and brain.
– Net synthesis of glycogen, protein and fat in most tissues.
– Long term changes in gene expression in all target tissues.
• Amylin acts on the brain to regulate appetite and body weight.
8989
insulin secretagogues• β cells contain a glucose sensing system, which requires glucose to
be metabolised. Islet cells have a membrane potential. They are excitable and communicate with one another.
• Other stimuli for insulin release include amino acids (alanine, leucine, arginine), 2-keto acids, peptide hormones (glucagon, GIP, GLP, CCK) and acetyl choline (autonomic nervous system).
• Free fatty acids have a biphasic effect: a short-term stimulation of insulin secretion is superseded by a long-term inhibition.
• Catecholamines (adrenaline, noradrenaline) inhibit insulin release via -receptors, weaker stimulation via -receptors.
• Glucagon is secreted by α cells in response to low blood glucose. It has widespread anti-insulin effects, but it is not a complete opposite and glucagon actually stimulates insulin release.
• Somatostatin from the δ cells suppresses both insulin and glucagon release. This hormone is also produced by the hypothalamus and suppresses growth hormone release from the pituitary.
9090
insulin microcrystals in secretory granules
insulin green, glucagon red, nuclei blue
Mouse pancreatic islet1
1Source: Solimena Lab, Med. Fac., University of Technology, Dresden, Germany
Mouse pancreatic beta cell1
insulin hexamers(with zinc)
9191
biphasic response to glucose
100
50
0
Insu
lin s
ecre
tion
(pg/
min
/isle
t)
11 mM glucose
0 15 60
Secondphase
Firstphase
Time (min)
100
50
0
Insu
lin s
ecre
tion
(pg/
min
/isle
t)
11 mM glucose
0 15 60
Secondphase
Firstphase
Time (min)
transient phase:
Release and depletion of “readily releasable pool” (RRP) – about 50 granules per cell (from 13,000 total). Caused by increased [Ca2+]i.
sustained phase:
Slow replenishment of RRP by priming granules from a reserve pool. 5-10 granules primed per cell per min. Requires glucose metabolism, possibly increasing [glutamate].
9292
glucose transporters
porter mechanism glucose Km
cellular location
tissues features
GLUT-1 passive 20 mM - brain, red cells, endothelium, β cells
constitutive porter
GLUT-2 passive 42 mM mobile kidney, ileum, liver, pancreatic β cells
low-affinity porter
GLUT-3 passive 10 mM apical neurones, placenta (trophoectoderm)
high-affinity porter
GLUT-4 passive 2 - 10 mM - skeletal muscle, heart, adipocytes
insulin-responsive
GLUT-5 passive - both widely distributed fructose transport
SGLT-1 sodium dependent
high affinity
apical small intestine, kidney tubules
high affinity uptake
SGLT-2 sodium dependent
low affinity
apical kidney proximal tubule
high capacity uptake
9393
glucose sensor (1)• The ATP concentration in most cells is high and constant, and it is
very difficult to detect any variations. Glucose metabolism in β cells is inefficient, so that ATP levels in β cells depend on glucose availability. This the essence of the sensing mechanism.
• Glucose entry into β cells uses low-affinity GLUT2 transporters, so that the uptake rate varies with the blood glucose concentration. Intracellular glucose concentration tracks the external supply.
• Glucose phosphorylation in β cells uses low-affinity glucokinase. The enzyme is not saturated with its substrate. The phosphorylation rate varies with intracellular glucose concentration, so in β cells the glycolytic rate ultimately depends on the glucose concentration in arterial blood.
• Glucose starvation affects the mitochondrial fuel supply, so in β cells the ATP concentration increases when blood glucose is high.
• Potassium efflux channels in β cells are inhibited by ATP. The channels close as ATP rises, depolarising and activating the cells.
9494
-cell glucose sensor (2)Glucose
Glucose
Glucose 6-phosphate
ATP:ADP
K+-
Ca2+
+
+
Glucokinase(Km 8 mM)
Metabolism
GLUT2(Km42 mM)
Insulin
K+ATP channel Voltage-gated
Ca2+ channel
ATP
ADP
H+
Glutamate
-+
priming
fusion
Glucose
Glucose
Glucose 6-phosphate
ATP:ADP
K+-
Ca2+
++
+
Glucokinase(Km 8 mM)
Metabolism
GLUT2(Km1 mM)
Insulin
K+ATP channel Voltage-gated
Ca2+ channel
ATP
ADP
H+
Glutamate
-+
priming
fusion
The -cell glucose uptake and phosphorylation systems are not saturated at physiological glucose concentrations.
9595
glucose sensor (3)• Depolarisation activates voltage-dependent calcium channels
(VDCCs), triggering calcium spikes and action potentials. This leads to exocytosis and insulin release from stored secretory granules.
• Islet tissue is also controlled by the autonomic nervous system. Many other compounds affect insulin release, using various signaling pathways:
– Leucine raises ATP through metabolism, but alanine and arginine directly depolarise the cells.
– Acetylcholine and cholecystokinin stimulate via phospholipase C, diacyl glycerol and IP3.
– Glucagon, GLP and GIP stimulate through G-proteins, adenyl cyclase and cyclic AMP.
– Catecholamines signal via β-receptors, G-proteins and adenyl cyclase, but inhibit the granule docking system via -receptors.
• Local gut hormones that stimulate insulin release are known as incretins.
9696
Oral hypoglycaemic drugs promoting insulin release
SO2 R2C
O
NHNHR1Sulfonylureas
R1 R2
Glimepiride(3rd generation drug)
H3CNCH3
CH3
O
CONHCH2CH2
N
NH
O
O
OH
O CH3
CH3
CH3
Repaglinide
Meglitinides
(short acting “prandial” blood glucose regulator)
(long duration of action)
9797
the sulphonylurea receptor
K+
sulphonylureas
ATP
Mutations in eitherFamilial persistanthyperinsulinemichypoglycemia of infancy
meglitinides
MgADP K+
sulphonylureas
ATP
Mutations in eitherFamilial persistanthyperinsulinemichypoglycemia of infancy
meglitinides
MgADP
NBF-1 NBF-2
SUR1 KIR6.2
(Photolabelled by the sulfonylurea glibenclamide)
(inward-rectifier K+ channel)
NBF-1 NBF-2NBF-1 NBF-2
SUR1 KIR6.2
This group of drugs all require functional islet tissue, and are therefore completely useless in patients with type 1 diabetes.
9898
model of the K+ATP channel
side view top view
ATP
From Mikhailov et al. (2005) EMBO J. 24, 4166-4175.
9999
the incretin effect
● Oral glucose causes 2-3-fold greater insulin secretion than equivalent intravenous load
● Two gut hormones are primarily responsible
– Glucose-dependent insulinotropic polypeptide (GIP), formerly known as gastric inhibitory polypeptide
– Glucagon-like peptide 1 (GLP-1), a 30-residue peptide
● GLP-1 stimulates insulin secretion and inhibits glucagon secretion
● In animals, GLP-1 stimulates -cell proliferation
100100
glucagon like peptide 1 is an “incretin”
From: Holst (2007) Physiol. Rev. 87, 1409-1439.
pancreasProglucagon
33 61
glucagon GLP-1
78 107
pancreas L-cell of intestine
Dipeptidylpeptidase IV in capillaries
t1/2 few minutes in circulation
GLP-1
secretion in response to meal
degradation
Sitagliptin and Vildagliptin, inhibitors of DPP4, are in clinical use
101101
mechanism of GLP-1 action on -cells
ATP cAMPPKA
Adenylate cyclaseGLP-1R
G-protein
N
cAMP-GEFII
Ion channels, exocytotic machinery
Enhanced insulin secretion
Gila monster
Exendin 4/ Exenatide /Byetta50% sequence identity to
GLP-1, full receptor agonist, resistant to DPP-IV
102102
insulin has many effects on cells
signals the fed state, promotes fuel storage
protein synthesis (translation)
mitogenesis (cell division)
Metabolism
• glycogen synthesis• glycolysis and fat biosynthesis• glucose uptake by muscle and fat
(Vmax increased 30-fold in minutes)
slow slowfast
103103
summary of insulin signalling
104104
summary of insulin signalling (1)
insulin binds to receptor, which auto-phosphorylates
105105
summary of insulin signalling (2)
phosphorylation of insulin receptor substrate
106106
summary of insulin signalling (3)
activation of phosphatidylinositol 3-kinase
107107
summary of insulin signalling (4)
Recruitment of PDK1 and PKB (=Akt) to the membrane
108108
summary of insulin signalling (5)
activation of PKB
109109
summary of insulin signalling (6)
phosphorylation of synip promotes fusion of storage vesicles with plasmalemma
110110
summary of insulin signalling (7)
without insulin, GSK3 keeps glycogen synthase inactive
111111
summary of insulin signalling (8)
steps 1 – 5 are the same as for GLUT4 activation
112112
summary of insulin signalling (9)
PKB phosphorylates and inactivates GSK3
113113
summary of insulin signalling (10)
protein phosphatase activates glycogen synthase
114114
summary of insulin signalling (11)
IRS binds to the small GTPase RAS through adaptor proteins
115115
summary of insulin signalling (12)
activated RAS activates Raf-1
116116
summary of insulin signalling (13)
Raf-1 activates MEK
117117
summary of insulin signalling (14)
MEK activates mitogen activated protein kinase (MAPK) which enters the nucleus
recycling GLUT4 porters – 1
118
Shepherd & Khan (1999) Glucose transporters and insulin action. NEJM 341, 248-257.
recycling GLUT4 porters – 2
119
Exercise increases insulin sensitivity, and independently stimulates vesicle recycling.
120120
Structure of the membrane-bound insulin receptor
S
S
S SS
S
135 kDa
90 kDa
extracellular
Activation loops
oligosaccharide
tyrosine kinase active sites
insulin
P P
121121
Tyrosine kinase activity of the receptor subunit is essential for transduction
Activation loop Autophosphorylation of Y 1158, 1162 & 1163 greatly enhances kinase activity of receptor towards other substrates
ATP-binding motif:G-X-G-X-X-G……..K(1030)
V X
(patient) (site-directed mutagenesis)
OR
normal insulin bindingbut
no kinase activity and no biological effect of insulin
122122
Phosphorylation of tyrosine residues allows access for protein substrates
Before auto-phosphorylation After auto-phosphorylation
Activation loop
Catalytic loop
substrate
123123
PTBPH
IRS-1, 2 etc. are “docking” proteins that couple multiple signalling pathways
PATP
Insulin receptor substrate 1(IRS-1) 131 kDa
(and IRS2-4, Shc,Gab-1, Cbl, etc.)
PATHWAY 1 PATHWAY 2
Y Y Y YY
Y
P P P
PNH3+
CO2-
SH2 SH2
124124
SH2 (SRC homology 2) domains recognise phosphotyrosine motifs
C-terminal SH2 domain from p85 subunit of phosphatidylinositol 3-kinase
Peptide containingphosphotyrosine
tyrosine
phosphate
Complex of SH2 domainand phosphotyrosyl peptide
+
125125
PTBPH
P
ATP
Y Y Y YY Y
P P P
PNH3+
CO2-
110 kDa85 kDa
P
OHOHOH
41P
P5
PIP2
P
OHOH
41 P
3
P
P5
PIP3
ADP
Phosphatidylinositol 3-kinase(PI 3-K) wortmannin
A key pathway involves phosphorylation of phosphoinositides on the 3-position
126126
Recruitment of Akt2 to the plasma membrane leads to its activation
P
OHOH
41 P
3
P
P5
PIP3
P
OHOH
41 P
3
P
P5
PIP3
PDK1
PH domain PH domain
PT309
Akt2
S 474P
Insulin
mTORC2
Akti-1/2Akt is also called PKB – protein kinase BPDK1 is 3-phosphoinositide-dependent protein kinase 1mTORC2 is mammalian target of rapamycin complex 2
127127Cheng et al (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews Drug Discovery 8, 627-644.
128128
mTORC
mammalian target of
rapamycin complex 1
andcomplex 2
129129
Targets for activated Akt2?
AS160/TBC1D4 and TBC1D1
PTB PTB S T RAB GAP
14-3-3
PTB PTB S T RAB GAP
PP
Rab GDPRab GTP
more active less active
Rab GDP
Rab GTP
RAB GEF RAB GEF
Rab10 in adipocytes, Rab8A in muscle?
Akt2
GSK3
glycogen metabolism
glucose transport
Synip S
Synip S
P
S
GSK3 S
P
glucose transport
130130
Where do Rabs, Synip and other factors act?
Synip S
Synip S
P
Rab GTP
insulin
Insulin ?
Synip = syntaxin 4-interacting protein
insulin
Rab GDP
Synaptobrevin 2
SNAP-23
Syntaxin 4
GLUT4
131131
Insulin-induced translocation of GLUT4-GFP
From: Oatey et al. (1997) Biochem. J. 327, 637-642.
Basal Insulin
midsection midsection
top top
extracellular
CO2-
1 2 3 4 5 6 7 8 9 10 11 12 GLUT4
GFP
MPSGFQQIGSE ......... 1aromatic motif (needed for endocytosis)
Targeting/sorting motifs
12 ..........RGELEYLGPDEND
acidic motif (needed for targeting to intracellular compartment)
See: Song et al. (2008) J. Biol. Chem. 283, 12571-12585 for more details.
132132
Insulin increases the rate of exocytosis of recycling GLUT4
From: Fletcher et al. (2000) Biochem. J. 352, 267-276.
early endosome
GLUT4 storage compartment/vesicles
glucose glucose
= sites where insulin/contraction may exert an effect
+
+
+-?Docking/fusion
Translocation
Budding
Endocyticretrieval
Sorting Retention
+/-
+
+
+-?
-
+
+
+-?
133133
What becomes of the glucose that is taken up by peripheral tissues?
glucose
glycogen
+ -
glucose
+
triacylglycerol
fatty acid
VLDL
glycerol-P
glucose
+
-
glucose
Unlike liver glycogen, muscle glycogen cannot be converted into blood glucose.
Peripheral tissues cannot use the glycerol released during triglyceride hydrolysis.
In adipocytes, the glucose is converted into triglycerides.
134134
Oral antidiabetic drugs that increase insulin sensitivity
• very widely used drug that improves insulin sensitivity
• decreases hepatic glucose production
• decreases intestinal absorption of glucose
• increases peripheral glucose uptake and utilization
• unrelated to most other oral hypoglycaemic drugs
• activates AMP-dependent protein kinase (AMPK)long-acting biguanide
Metformin
wrong kind of AMP?• There are two different kinds of AMP in cells, which work
independently, and transmit different signals.
• 3’5’cyclic AMP is produced by adenyl cyclase in the plasmalemma, usually in response to some circulating hormone that signals via G-protein coupled receptors (GPCRs).
• 3’5’cyclic AMP often activates protein kinase A (PKA)
• linear 5’ AMP is produced by myokinase located in the mitochondrial intermembrane space:
ATP + AMP = ADP + ADP
• mitochondria actively export of ATP and take up ADP, driven by the mitochondrial membrane potential.
• [AMP] is vanishingly small in healthy cells, but rises rapidly on any threat to the cellular energy supply.
136136
AMPK• Most important cellular energy gauge.
• Activated by linear 5’ AMP & upstream kinases LKB1 and calmodulin-dependent protein kinase (CaMKK).
• Steers metabolism away from non-essential synthetic activities towards energy-yielding processes that are important for cell survival.
• Activity is normally low because [AMP] is kept low by the myokinase reaction: AMP + ATP = ADP + ADP
• Phosphorylates and inactivates HMG-CoA reductase (sterol biosynthesis), acetyl-CoA carboxylase (fatty acid biosynthesis) and TORC2 (PEPCK transcription).
• Activated by the fat cell hormone adiponectin, and also by metformin and the thiazolidinediones.
the hunting of the SNARK...• nonsense poem by Lewis Carroll 1874• paper by Koh et al (2010) Sucrose nonfermenting
AMPK-related kinase (SNARK) mediates contraction-stimulated glucose transport in mouse skeletal muscle. PNAS 107, 15541–15546.
• Insulin is required for glucose uptake by resting skeletal muscle expressing GLUT4 porters.
• During exercise, muscle takes up glucose without insulin, and the sensitivity to insulin is also enhanced.
• This effect is mediated by one member from a family of AMP dependent protein kinases that play a central role in the regulation of energy metabolism.
• Remember that AMPK responds to linear 5’-AMP, and differs from PKA which responds to cyclic 3’5’-AMP 137
138138
Oral antidiabetic drugs that increase insulin sensitivity
Thiazolidinediones (glitazones)
Rosiglitazone (Avandia, GSK)SNH
N N
CH3
O
O
O
• Increase insulin sensitivity of liver, skeletal muscle and adipose tissue.
• Nearly normalise rates of hepatic glucose production.
• Cause 40 - 60 % increase in insulin-mediated glucose disposal
• Rosiglitazone recommended for treatment of a subset of Type 2 diabetic patients by NICE in 2000, but concerns about the risk of cardiovascular disease raised in 2007.
139139
Thiazolidinediones stimulate transcription via PPAR
transcription
peroxisome proliferatoractivated receptor-
retinoid X receptor
DR-1 sites
PPAR RXR
Rosiglitazone in ligand-binding domain (LBD)
● Endogenous ligands: Unsaturated and oxidized fatty acids, eicosanoids and prostaglandins
● Ligand binding to PPAR or RXR promotes dimerization, interaction with DNA and conformational changes in the LBD that control recruitment of transcriptional regulators
Genes involved in adipogenesis and lipogenesis e.g. GLUT4, adiponectin, etc.
140140
How do thiazolidinediones work?
↑TG storage
FFA
PPAR activationTZDs
↓ lipid accumulation↑ FA oxidation liver
↓ lipid accumulation↑ glucose uptake
muscle
↓ TNF, resistin↑ adiponectin
141141
Targets for new antidiabetic drugs?
PI3K
PTEN
PI(4,5)P2 PI(3,4,5)P3
insulinreceptor
insulin
P
IRS-1 IRS-1
P
PTP1B
PTP1B
(protein tyrosine phosphatase 1B)
(phosphatase and tensin homologue on chromosome 10)
Y
P
IRS-1 S
P
JNK
142142
obesity and insulin-resistance
Obesity and type 2 diabetes mellitus is associated with:
● expression of GLUT4 in adipose tissue
● ~ normal expression of GLUT4 in muscle liver muscle
insulin
glucose
glucose
pancreas
adipocytes
glucose
Selective knockout of GLUT4 expression in adipocytes leads to insulin-resistance in liver and muscle.
Therefore intact adipocytes must secrete something in response to glucose which improves insulin sensitivity in other tisses.
143143
adipocytes secrete “adipokines”
COO-
Free fatty acids (FFA)
Tumour necrosis factor (TNF)
ResistinAdiponectin (Acrp30)
ObesityObesity
TNF inhibits insulin signalling
Transgenic mice lacking TNF gene, or genes for TNF receptors are protected from obesity-induced insulin resistance
Adiponectin potentiates the effect of insulin
Transgenic mice lacking adiponectin are moderately insulin resistant.
Resistin (10 kDa protein) impairs insulin action in rodents, but role in humans is moot.
144144
Adiponectin shares a signalling pathway with biguanides in liver
N C
NH
NH C
NH
NH2CH3
CH3
↑[AMP]:[ATP]
Metformin (glucophage)
↓hepatic gluconeogenesis
?
Mitochondrial respiratory complex 1
AMP-activated protein kinase
(AMPK)
P
T172
LKB1
AdipoR2
Decreased expression of gluconeogenic enzyme PEPCK
Hypoxia
Metformin:
● Suppresses hepatic gluconeogenesis ● Increases insulin-stimulated skeletal
muscle glucose uptake● Reduces gastrointestinal glucose
absorption (probably by stimulating conversion to lactate)
● Lowers plasma [triglyceride] and [FFA]● Useful for obese patients because, unlike
sulfonylureas, doesn’t cause weight gain
145145
Mechanism of TNF and FFA effects – serine phosphorylation of IRS-1
TRAF-2
Fil
am
in
PKC
TNF
TNF receptor
insulinreceptor
insulin
COO-
FFA
JNK
MAP2K4
MAPKKK
OBESITY
PTBPH
Y S Y Y Y
P P P
NH3+
CO2-
S S
P
S
P
S307
IRS-1
metabolism
146146
hunger, satiation and satiety
• We all understand hunger, but satiation and satiety cause confusion.
• Satiation refers to physiological processes that promote meal termination.
• Satiation results from a coordinated series of neural and hormonal signals produced by the gut in response to a meal.
• Satiation is normally pleasant, but includes feel bloated and sick.
• Satiety refers to physiological processes that delay the start of the next meal.
147147
weight regulation is very precise
• Annual food intake is ~ 4.4GJ per person year
• 20kg gained over 10 years is about 590MJ in total, but only 1.3% excess over requirements.
There are two regulatory components:
• Hunger varies inversely with body weight
• Metabolism varies directly with body weight
If people lose weight their desire to eat more food becomes very strong, while at the same time their physical activity and basal metabolic rate decline, which conserves their remaining fat stores.
148148
achieving energy balance
Schwartz et al (2000) Central nervous system control of food intake Nature 404, 661 - 671
149149
it is very difficult to lose weight…Successful weight loss offers clear health benefits for those most seriously overweight, but...
• The multiple interlocking feedback loops conspire against the patient.
• Gastric surgery is the most effective method, but it is expensive and impractical for whole populations.
• The available drugs have limited effectiveness and significant side-effects.
• It is very difficult to maintain more than 10% cut in body weight by diet and lifestyle changes.
• There is a marked tendency to regress.
• Lifestyle changes must be permanent. One cannot diet to a target, and then return to previous habits without regaining all the weight.
150150
regulatory systems are redundant
• It has proved difficult to dissect the mechanisms regulating body weight using gene knockout or inhibitors because the systems are highly redundant, with cross-talk between the channels, so that individual alterations have limited effect.
• Multiple sensors around the body report total energy stores and the current state of play.
• Multiple sensors in the gut accurately report the size and composition of the current meal.
• Multiple pathways within the central nervous system process the input data and decide what must be done.
• Multiple effector systems (conscious, autonomic, hormonal) control feeding patterns, reproductive behaviour and the storage and disposal of the food previously consumed.
151151
multiple layers of control
• The enteric nervous system within the gut can organise the efficient digestion and storage of an entire meal without needing external assistance.
• The autonomic nervous system (ANS) adds a subconscious supervisory layer. There are two key regions with the brain: (1) the hypothalamus and (2) the nucleus of the solitary tract, whose main communication channel is the vagus nerve.
• The forebrain adds a layer of conscious decision making and perception, but it has limited ability to over-ride the decisions of the hypothalamus and the solitary tract.
152152
central control systems
153153
hindbrain details
• The solitary tract matches the GI tract, front to rear, and communicates with GI tract via cranial nerves.
• Taste information is transmitted via the facial (VII) and glossopharyngeal (IX) nerves.
• Stomach & bowel signal via the vagus nerve (X).
154154
vagus nerves
• The paired vagi are the longest of the cranial nerves (the latin name means “wandering”).
• Left and right branches leave the base of the skull, and run close to the oesophagus to innervate the heart, viscera and reproductive tract.
• The two vagi carry afferent sensory information about meal size and chemical composition from the gut to the brain.
• The vagi also carry efferent “motor” commands from the brain that modulate secretion of hormones and digestive juices, peristalsis and metabolism in the target organs.
• Enteric neurones manage the detailed program.
155
enteric nervous system (1)
156156
enteric nervous system (2)
• The enteric nervous system is a complex, multi-layered network, which covers the entire length of the GI tract from oesophagus to anus.
• It contains about 100 million neurones – roughly as many neurones as the spinal cord.
• It receives inputs from numerous mechanical and chemical sensors within the gut, and sends outputs to smooth muscles and glands.
• It independently regulates peristalsis, secretion of mucus and enzymes, local blood flow and responses to noxious stimuli.
157157
monitoring total fat reserves
• The key hormone is leptin, a cytokine secreted by well-filled adipocytes.
• There are leptin receptors in the arcuate nucleus in the hypothalamus, which is outside the blood – brain barrier.
• Leptin signals via the JAK/STAT pathway controlling nuclear gene expression, and also via ATP-sensitive K+ channels.
• Leptin is also required for sexual maturation and fertility.
158158
monitoring the current position
• Insulin reflects more recent food ingestion and reinforces the effects of leptin on the arcuate nucleus.
• The hypothalamus and solitary tract contain their own glucose sensors, and receive data from other glucose sensors in the pancreas, carotid bodies, and (in rodents) portal vein.
• Although hypoglycaemia causes hunger and activates the sympathetic nervous system, hyperglycaemia has little effect.
159159
the solitary tract monitors the gut
160160
there are many signals from the gut
• The signals vary with time as food passes through the gut.
• Messages reflect the quantity and quality of the ingested food.
• These signals inform the rest of the body, but also control local gut reflexes that match secretion, peristalsis and absorption to the quantity and quality of the food that has been eaten.
161161
time course for hormone secretion
Adan et al (2008) Trends in Pharmacological Sciences 29, 208-217
162162
entero-endocrine cells
• A family of entero-endocrine cells line the gut wall from the mouth to the colon, and continually “taste” the gut contents.
• These cells also receive a wide range of “gating” input signals and send a variety of neural and hormonal output signals.
• There is considerable homology between the sensing and signalling mechanisms in different regions of the gut.
• Many different output molecules encode the information being transmitted.
163163
Berner-Hansen & Witte (2008) The role of serotonin in intestinalluminal sensing and secretion. Acta Physiologica 193, 311-323.
• Serotonin (5-hydroxy tryptamine, 5-HT) is one of many transmitters that are used within the gut.
• Cells that signal using 5-HT are known as entero-chromaffin (EC) cells.• These cells are particularly common in the duodenum.• One important signalling route involves capsaicin-sensitive TRPV1
channels. (TRP=transient receptor potential)• Capsaicin is an active ingredient in curries and hot chilli sauce.
164164
PeptideMain site of synthesis
Receptors mediating feeding effects
Sites of action of peripheral peptides germane to feeding
Effect on food intake
Hypothalamus Hindbrain Vagus
CCKProximal intestinal I cells
CCK1R X X X down
GLP1Distal-intestinal L cells
GLP1R X? X? X down
OxyntomodulinDistal-intestinal L cells
GLP1R etc X down
PYY3–36Distal-intestinal L cells
Y2R X X down
Enterostatin Exocrine pancreasF1-ATPase subunit
X down
APO AIVIntestinal epithelial cells
Unknown X X down
PP Pancreatic F cells Y4R, Y5R X X down
Amylin Pancreatic cells CTRs, RAMPs X X down
GRP and NMBGastric myenteric neurons
GRPR X X down
Gastric leptinGastric chief and P cells
Leptin receptor ? ? X down
GhrelinGastric X/A–like cells
Ghrelin receptor X X X up
165165
entero-endocrine cells
Cummings & Overduin (2007) J. Clin. Invest. 117, 13-23.
166166
TRP proteins
• TRP stands for “transient receptor potential” which is a mutation first observed in Drosophila visual pathways.
• Hundreds of additional TRP proteins have since been identified, and are now grouped into five major classes, with a wide range of functions.
• Many (but not all) of them function as sensory transducers or transmembrane ion channels.
• There is a recent review by Venkatachalam & Montell (2007) TRP Channels. Ann. Rev. Biochemistry 76, 387-417
• TRPM5 is involved in taste transduction.
167167
168168
AGRP
• Agouti-related protein (AGRP) is named after a similar gene that controls hair colour in rodents.
• Powerful antagonist of the MC3R and MC4R melanocortin receptors in the hypothalamus.
• Obese patients have elevated plasma levels of AGRP, and over-expression of AGRP in animal models leads to obesity.
• Brain injections of AGRP stimulate feeding
• No known drugs in development.
169169
amylin
• Amylin is a peptide hormone co-released with insulin by pancreatic cells.
• Produces a feeling of satiation, and assists in the regulation of food intake.
• Pramlintide acetate is an amylin analogue that was licensed by the FDA in 2005
• Inconvenient to use (several injections per day) but it is an effective drug with few side effects.
170170
CART
• Cocaine and amphetamine regulated transcript (CART) is a neuropeptide precursor protein that is abundant in the hypothalamus. It is up-regulated after cocaine or amphetamine administration.
• CART-derived peptides reduce food intake when injected into the third cerebral ventricle.
• CART probably has many other functions within the central nervous system.
• It has proved difficult to identify CART receptors.
• No known drugs in development.
171171
cholecystokinin
Cholecystokinin (CCK) is secreted by entero-endocrine cells in the duodenum in response to the partially digested output from the stomach, which is called chyme. Fatty high-protein meals are particularly effective.
• CCK delays gastric emptying• stimulates pancreatic enzyme output• causes the gall bladder to contract • has a weaker incretin effect than GLP-1• produces a sensation of fullness or satiation• signals to the brain via the vagus nerve• causes satiation rather than satiety and leads to small,
frequent meals but no weight loss
172172
endocannabinoids (1)
• Anandamide and 2-arichidonoyl glycerol are “genuine” cannabinoids, which bind to CB1 and CB2 receptors.
• CB1 agonists increase food intake: “getting the munchies”.
• Oleoyl ethanolamide suppresses food intake but it is not a “real” cannabinoid. It works through PPAR- .
• Palmitoyl ethanolamide has anti-inflammatory effects.
173173
endocannabinoids (2)
• Cannabinoids are not stored in secretory vesicles like most neurotransmitters, but are synthesised on demand from arachidonyl phospholipids.
• Their action is terminated by cellular uptake and hydrolysis to free arachidonic acid.
• Rimonabant is a CB1 receptor antagonist, which is effective against nicotine addiction.
• Rimonabant reduces appetite and achieves significant weight loss.
• Rimonabant was never approved for use in America. The European licence was withdrawn because patients were at increased suicide risk.
174174
ghrelin
• Ghrelin is a 28-residue peptide secreted by endocrine cells within the gastric sub-mucosa.
• The hormone is released by the empty stomach and produces sensations of hunger.
• It acts on the hypothalamus to stimulate growth hormone release by the pituitary.
• It is also produced locally by neurons within the hypothalamus, and in other parts of the intestine.
• It antagonises leptin, increases metabolic efficiency and stimulates eating behaviour, resulting in weight gain.
• It is thought that the effective weight loss achieved by gastric surgery may reflect a fall in ghrelin output.
175175
glucagon like peptide 1
• Wren & Bloom (2007) Gastroenterology 132, 2116-2130.• Differential processing of preproglucagon • GLP-1 = glucagon-like peptide 1• MPGF = major proglucagon fragment• GRRP = glicentin-related pancreatic peptide
176176
insulin• Insulin reduces food intake and plays a major part in
appetite regulation.
• Gene knockout shows that lack of either brain insulin receptors or insulin receptor substrate 2 (IRS2) results in hyperphagia, obesity and female infertility.
• Insulin promotes phosphorylation of leptin receptors and JAK2, which enhances the phosphorylation of STAT3 in the presence of leptin.
• Insulin levels are often raised in type 2 diabetes which is associated with insulin resistance and obesity.
177177
leptin
• Leptin is a cytokine released by bloated fat cells and also by the stomach.
• It acts on the arcuate nucleus within the hypothalamus to suppress eating behaviour and also increases energy expenditure.
• Leptin production rises with increasing fat cell mass.
• ob/ob mice fail to make leptin and are grotesquely obese, as are db/db mice that lack the leptin receptor.
178178
Leptin
Leptin can modulate the responses from enteroendocrine cells, autonomic nervous system, the hypothalamus and the solitary tract.
179179
POMC
• Pro-opiomelanocortin (POMC) Initial transcript is cleaved to yield MSH and ACTH, transmits many other messages within the brain.
• Four distinct 7-transmembrane G-protein linked receptors.
• MC1R controls skin pigmentation.
• MC2R is the ACTH receptor.
• MC3R controls the conversion of dietary fuel into fat.
• MC4R regulates food intake and energy expenditure.
180180
MSH and MCH
• MSH is melanocyte stimulating hormone,which darkens pigmentation in lower vertebrates.
• MSH is the downstream signal from POMC / CART neurones, and suppresses food intake.
• MCH is melanocyte concentrating hormone, which lightens pigmentation in lower vertebrates.
• MCH delivers an orexigenic signal
• MCHR1 receptor antagonists reduce food intake and increase energy expenditure in animal tests, but have not yet been approved for humans.
181181
NPY
• Neuropeptide Y (NPY) is a highly conserved 36-residue peptide, widely distributed in vertebrate nervous systems.
• Many neurosecretory and cardiovascular functions.
• At least five classes of NPY receptor distributed over a wide range of tissues.
• Powerful orexigenic (appetite-promoting) signal within the hypothalamus.
• Activates a neural pathway eventually leading to the nucleus of the solitary tract.
• NPY is over-produced in obese, leptin-deficient mice.
• Leptin + NPY double knockouts are less obese, which suggests that NPY mediates the over-feeding observed in leptin-deficient animals.
182182
orexins
Orexins A & B are neurotransmitters (otherwise known as hypocretins 1 & 2) derived from a common precursor.
• Discovered in 1998 with their G-protein linked receptors OX1-Rs and OX2-Rs.
• Major role in arousal and food seeking behaviour.
• Damage to the orexin signalling system leads to narcolepsy.
183183
peptide YY• Peptide YY (PYY) is a 36-residue peptide secreted by
endocrine cells in the lower small intestine, pancreas and colon.
• It slows digestion and reduces the consumption of food.
• PYY inhibits gastric acid secretion and gastric emptying, pancreatic enzyme secretion and gut motility.
• Acts on the arcuate nucleus in the hypothalamus to suppress appetite and reduce food intake.
• Reduces food intake by 33% in obese subjects, who are normally leptin resistant.
• PYY shows sequence homology to orexigenic NPY and to pancreatic polypeptide (PPY) from F cells in islets.
184184
signalling from gut to brain
185185
hypothalamic nuclei
186186
arcuate nucleus
187187
melanocortin signalling in the arcuate nucleus.
•Leptin activates POMC neurones releasing -MSH which binds to MC4R receptors.•Ghrelin activates NPY neurones, releasing
AGRP & NPY
diagnosing the metabolic syndrome
measurementhealthy range
metabolicsyndrome
comments pathology
body mass index 18 - 25 kg/m2 > 30 kg/m2 includes muscle
abdominalobesity
waist : hip ratio (male) 0.85 > 0.9alternativemeasures for abdominalobesity
waist : hip ratio (female) 0.7 > 0.85
waist (male) < 94 cm (IDF) > 102 cm (NCEP)
waist (females) < 80 cm (IDF) > 88 cm (NCEP)
fasting blood glucose 4.5 - 5.5 mM > 7 mM ideally 5 mM type 2diabetesfasting blood insulin 5 - 10 µU/mL 20 - 40 µU/mL 1 µU/mL = 6.94 pM
fasting triglycerides 0.5 - 1.5 mM > 1.7 mM raised after meals
dislipid-aemia
total cholesterol 3.5 - 5.5 mM > 6 mM ideally 5 mM
LDL-cholesterol 2.0 - 3.0 mM > 3.3 mM "bad" cholesterol
HDL-cholesterol 1.1 - 2 mM < 0.9 mM "good" cholesterol
blood pressure (mm Hg) 120 / 80 > 140 / 90 systolic / diastolic hypertension
C-reactive protein < 3 mg/L > 3 mg/L quantifies inflammation
IDF International Diabetes Federation; NCEP National Cholesterol Education Program
waist measurement
mostly white Europeans > 50 years
Waist circumference is increasingly seen as the best indicator for the metabolic syndrome. Ideally, it should be measured early morning, after an overnight fast.
Cameron et al
(2010)
Cut-points for Waist
Circumferencein Europids and South Asians
Obesity 18, 2039–2046.
doi: 10.1038/oby.2009.45
5
Note the log – linear relationship between waist measurement and diabetes risk
191191
energy stores for a 70kg male
5mM blood glucose is only sufficient for a few minutes normal activity
body composition
[all in kg] lean man obese man comments
weight 70 100
water 42 47
protein 12 13 about 50% can be metabolised
fat 12 35 almost all can be metabolised
rest 4 5 bones, glycogen etc
The bulk of our energy is stored as fat, but this occupies relatively little space because it has a very high energy density and the water content is low. This obese man has 23kg of superfluous fat, corresponding to a three-fold expansion of the “normal” energy store, but this brings with it only 1kg of additional protein and 5kg of body water.
energy content of foods and tissuesdietarycomponent
energy densitytypicalwatercontent
effectiveenergycontentkJ/g kcal/g
dietary fibre 8 2 variable maybe 1 kJ/g
ethanol 29 7 60 - 96% wine 3.6 kJ/g
oils and fats 37 9 zero 37 kJ/g
proteins 17 4 75% ~ 4 kJ/g
refined sugar 17 4 zero 16 kJ/g
starches 17 4 25 - 95% 2 - 8 kJ/gIn practice, the energy density (and flavour!) of real foods is hugely dependent on the fat and refined sugar contents, because these have very high energy densities. Composition varies with preparation and cooking methods. The overall water content is also important.
194194
strategies for weight lossThere are three basic approaches:
1. Decrease food absorption
– Lower energy meals
– Less efficient digestion
– Smaller meals (quicker satiation)
– Less frequent meals (longer satiety)
– Appetite-suppressing drugs
2. Block lipid biosynthesis
– Carbonic anhydrase inhibitors
3. Increase food oxidation
– Less efficient metabolism
– Increased physical activity
Examples exist of all three strategies.
maintaining muscle mass• Most people on a weight loss diet want to lose adipose
tissue mass, while retaining their muscles intact.• Unfortunately, sudden withdrawal of food in humans
produces a “profligate” phase of metabolism, where the individual searches avidly for food and blood glucose is initially maintained at the expense of muscle proteins.
• It takes several days to establish the long-term fasting pattern, where triglycerides provide the major source of energy, the glycerol moiety being converted into blood glucose, while some of the fatty acids are converted into acetoacetate and hydroxybutyrate which reduce cerebral glucose requirements.
• This is why “crash” diets are generally ineffective, unless the subject sticks to them for several weeks. 195
196196
hormonal control of metabolism
hormonal effects
on
insulin glucagon / adrenalin
growth hormone
cortisol TNF – α and
IL – 1
sugars glycolysis gluconeo-genesis
gluconeo-genesis
gluconeo-genesis
glycolysis
glycogen synthesis breakdown synthesis redistribute to muscle
breakdown
proteins synthesis breakdown synthesis breakdown breakdown
fats synthesis lipolysis lipolysis redistribute to abdomen
breakdown
In addition, cortisol has immunosuppressive effects and thyroidhormones increase general activity and basal metabolic rate.
conventional wisdom• In order to avoid the adverse effects of “yo-yo dieting”
the usual recommendation is that subjects reduce their energy intake by about 500 kcals/day and aim to shed about 10% of their body weight over several months.
• It is very difficult to stick to this, and most diet studies have large drop-out rates.
• Subjects are conventionally advised to reduce their fat intake below 30% of energy intake, with no more than 10% saturated fat, and to increase their intake of fruit and vegetables (providing bulk and vitamins) while obtaining most of their energy from slowly-digested carbohydrates with a low glycaemic index.
• This approach leaves many people feeling ravenously hungry and bad-tempered almost all the time.
197
198
the heretics• The problem with the conventional wisdom is that fats
provide much of the flavour and texture in foods, and many satiation mechanisms are largely based on fat.
• People also point out the application of the conventional wisdom has coincided with the largest obesity epidemic that the world has ever seen.
• An alternative school of thought recommends a high-fat, high-protein, low-carbohydrate diet. Although commonly associated with Dr Atkins, this approach is actually over a century old.
• High-fat, low-carb diets trigger the physiological satiation systems, so the subjects do not feel hungry and the diets can be eaten ad lib.
• Reduced need for insulin may help diabetics. 199
Mediterranean diets• Epidemiological studies show that many Mediterranean
countries have relatively low rates of diabetes and cardiovascular disease.
• This has stimulated interest in Mediterranean diets, which allegedly have a high content of raw vegetables, nuts, olive oil and red wine.
• Olive oil is mostly monounsaturated, but contains some polyunsaturates as well.
• The nuts contain a good mixture of nutrients and are also slow to digest.
• The red wine contains anti-oxidants, and is also known to raise HDL cholesterol.
200
so which diet is best?• The scientific dispute has taken on an almost religious
ferocity, with prophets of doom on both sides.• Volunteers are often reluctant to stick to their diets and
very few studies have continued for long enough to draw reliable conclusions.
• It is almost impossible in this area to achieve the gold standard of a “randomised, prospective, double-blind cross-over design”.
• Many studies examine “surrogate end points” which are easily and cheaply measured, but the only real test is to wait for several years and record whether the subjects are alive or dead.
• There has been considerable interest in an important study by Shai et al (2008) NEJM 359, 229- 241. 201
202202
low fat diet details
• The low-fat, restricted-calorie diet was based on American Heart Association guidelines.
• They aimed at an energy intake of 1500 kcal per day for women and 1800 kcal per day for men, with 30% of calories from fat, 10% of calories from saturated fat, and an intake of 300 mg of cholesterol per day.
• The participants were counselled to consume low-fat grains, vegetables, fruits, and legumes and to limit their consumption of additional fats, sweets, and high-fat snacks.
203203
Mediterranean diet
• The moderate-fat, restricted-calorie, Mediterranean diet was rich in vegetables and low in red meat, with poultry and fish replacing beef and lamb.
• They restricted energy intake to 1500 kcal per day for women and 1800 kcal per day for men, with a goal of no more than 35% of calories from fat; the main sources of added fat were 30 to 45 g of olive oil and a handful of nuts (five to seven nuts, <20 g) per day.
• The diet is based on the recommendations of Willett and Skerrett.
204204
low carbohydrate diet
• The low-carbohydrate, non–restricted-calorie diet aimed to provide 20 g of carbohydrates per day for the 2-month induction phase and immediately after religious holidays, with a gradual increase to a maximum of 120 g per day to maintain the weight loss.
• The intakes of total calories, protein, and fat were not limited.
• Participants were counselled to choose vegetarian sources of fat and protein and to avoid trans fat.
• The diet was based on the Atkins diet.
205205
Which is the best weight-loss diet?
206206
low carbs beats low fat
more on lifestyle...
• Two papers were recently published online before print which seem highly relevant to the prevention and treatment of type 2 diabetes:
• Uusitupa et al (2010) Impact of positive family history and genetic risk variants on the incidence of diabetes – the Finnish Diabetes Prevention Study. Diabetes Care doi:10.2337/dc10-1013
• Salas-Salvadó et al (2010) Reduction in the Incidence of Type 2-Diabetes with the Mediterranean Diet: Results of the PREDIMED-Reus Nutrition Intervention Randomized Trial. Diabetes Care doi:10.2337/dc10-1288
• Paste the doi into http://dx.doi.org/ to see the abstracts.
207
Uusitupa et al• Studied the effects of family history of diabetes and 19 known
genetic risk loci on the effectiveness of lifestyle changes.
• Subjects with impaired glucose tolerance were randomized into control (n=257) and intervention (n=265) groups. The mean follow-up was 6.2 years.
• Lifestyle intervention, aimed at weight reduction, healthy diet and increased physical activity, lasted for 4 years (range 1-6 years).
• Family history and genetics had no measurable effect on the outcome.
• The only factor with a significant effect was the lifestyle intervention (hazard ratio 0.55, 95% confidence limit 0.41 – 0.75, p<0.001)
• These results emphasize the effectiveness of lifestyle intervention in reducing the risk of diabetes in high risk individuals independent of genetic or familial risk of type 2 diabetes.
208
Salas-Salvadó et al• 418 nondiabetic subjects aged 55-80 years at high cardiovascular risk
were randomized to education on a low-fat diet (control group) or one of two Mediterranean diets, supplemented with either free virgin olive oil (1 litre/week) or nuts (30 g/day).
• Diets were ad libitum and no advice on physical activity was given.
• After a median follow-up of 4.0 years, diabetes incidence was 10.1% in the Mediterranean-diet with olive oil group, 11.0% in the nuts group, and 17.9% in the control group.
• Diabetes incidence was 52% lower in the Mediterranean groups.
• In all study arms, increased adherence to the Mediterranean-diet was inversely associated with diabetes incidence.
• Diabetes risk reduction occurred in the absence of significant changes in body weight or physical activity.
• Mediterranean diets without calorie restriction appear to be effective in the prevention of diabetes in subjects at high cardiovascular risk. 209
210210
childhood obesity
• There is great concern about increasing obesity among children, and the likely continuation into adult life.
• The Avon Longitudinal Study has followed a large cohort of parents and children living near Bristol from birth.
• Ness et al (2007) PLoS Medicine 4(3), e97 conclusively demonstrated that obesity was directly linked to physical activity quintiles in boys and girls aged 12.
211211
thermogenesis in brown fat
212212
Year Drug Mechanism Side effects
late 19th cent. Thyroid hormone Increases metabolic rate Hyperthyroidism
1920s Dinitrophenol Mitochondrial uncouplingCataracts, neuropathy, cardiac failure
1930sAmphetamines (phentermine, diethylpropion, phendimetrazine)
Dopamine–noradrenaline-reuptake inhibitor, releaser, sympathomimetic drugs
Addiction, myocardial infarction, stroke
1950s Phenylpropanolamine Sympathomimetic Stroke
1960sRainbow pills (mixture of digitalis, amphetamine and diuretics)
Mixed Fatalities: digitalis has a narrow therapeutic index
1990sFen-phen (mixture of fenfluramine and phentermine)
5-HT-reuptake inhibitor and releasing agent with sympathomimetic
Cardiac valvulopathy
Recently withdrawn
Rimonabant Cannabinoid CB1 receptor antagonist Depression, anxiety
Sibutramine 5-HT–noradrenaline-reuptake inhibitor Tachycardia, hypertension
Rosiglitazone Thiazolidinedione – PPAR- Heart failure
Currently usedOrlistat Gastric lipase inhibitor
Flatulence and diarrhoeaAcarbose Amylase inhibitor
[epilepsy] TopiramateAntiepileptic drug targeting multiple proteins, carbonic anhydrase inhibitor
Memory impairment, depressive symptoms
[depression] Fluoxetine 5-HT-reuptake inhibitor Nausea, diarrhoea
[ADHD] Atomoxetine Noradrenaline-reuptake inhibitor Dry mouth, palpitations
[epilepsy] ZonisamideAntiepileptic drug targeting multiple proteins, carbonic anydrase inhibitor
Memory impairment
[depression and smoking]
Bupropion Dopamine–noradrenaline-reuptake inhibitor Dry mouth, insomnia
213213
drugs that work• In contrast to the generally disappointing results from
appetite suppressants -
• ACE inhibitors and angiotensin receptor antagonists routinely deliver substantial reductions in blood pressure and improved survival
• Diuretics such as Frumil (furosemide + amiloride) reduce central venous blood pressure after heart failure
• HMG-CoA reductase inhibitors “statins” deliver roughly 10% fewer adverse vascular events for each 0.65mM reduction in LDL-C. [Delahoy et al (2009) Clinical Therapeutics 31, 236 – 244 provide a meta-analysis of 155,613 subjects, 6321 vascular deaths, 23791 major vascular events, 11357 coronaries and 4717 strokes]
214214
Ludman et al (2009) Pharmacology & Therapeutics 122, 30–43.
215215
cholesterol turnover in the body
216216
regulating HMG-CoA reductase
Espenshade & Hughes (2007) Regulation of Sterol Synthesis in Eukaryotes. Annu. Rev. Genet. 41, 401–27
• SREBP – sterol regulatory element binding protein (helix – loop – helix / leucine zipper)
• Insig – insulin induced gene (resident ER protein, binds oxysterols involved in bile acid synthesis)
• Scap – SREBP cleavage activating protein (binds cholesterol)
• S1P – site one protease (Golgi)
• S2P – site two protease (Golgi)
217217
In the absence of sterols, HMGR does not bind Insig and is present at high levels. In the presence of lanosterol or oxysterols, Insig mediates the ubiquitinylation (Ub) and subsequent degradation of HMGR by the proteasome through interactions with the E2 conjugating enzyme Ubc7, the E3 ubiquitin ligase gp78, and the ATPase VCP/p97. Geranylgeraniol (GG-OH) enhances HMGR degradation through an unknown mechanism that acts downstream of ubiquitinylation.
218218
219219
drugs for obesity, diabetes & cardiovascular diseaseexample type principal targets typical indication
ramipril ACE inhibitor arteriolar smooth muscle hypertension
valsartan AR blocker arteriolar smooth muscle hypertension
metoprolol -blocker cardiac muscle hypertension
nifedipine Ca++ antagonist cardiac & smooth muscle hypertension
frumil diuretic kidney tubules (loop of Henle) heart failure
nitroglycerine organic nitrate venous smooth muscle angina
aspirin NSAID non-specific COX1 & COX2 old age?
clopidogrel anti-platelet platelet ADP receptor atherosclerosis
heparin anti-coagulant vascular endothelium atherosclerosis
warfarin anti-coagulant liver (clotting factor synthesis) atherosclerosis
streptokinase clot dissolution blood clots acute MI
lovastatin statin liver HMG-CoA reductase dislipidaemia
gemfibrozil fibrate PPAR- in many tissues dislipidaemia
metformin biguanide liver AMPK type 2 diabetes
exenatide incretin pancreatic -cells type 2 diabetes
glipizide sulphonylurea pancreatic -cells type 2 diabetes
pioglitazone thiazolidinedione PPAR- in many tissues type 2 diabetes
acarbose amylase inhibitor small intestinal lumen type 2 diabetes
orlistat lipase inhibitor small intestinal lumen diabetes, obesity
sibutramine SSRI central nervous system obesity